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X-linked adrenoleukodystrophy (X-ALD) is a hereditary disorder of peroxisomal metabolism biochemically characterized by the
accumulation of very long chain fatty acids (VLCFA), particularly hexacosanoic acid (C26:0) and tetracosanoic acid (C24:0) in different
tissues and in biological fluids. The disease is clinically characterized by central and peripheral demyelination and adrenal insufficiency,
which is closely related to the increased concentrations of these fatty acids. However, the mechanisms underlying the brain damage in X-
ALD are poorly known. Considering that free radical generation is involved in various neurodegererative disorders, like Parkinson disease,
multiple sclerosis and Alzheimer’s disease, in the present study we evaluated various oxidative stress parameters, namely
chemiluminescence, thiobarbituric acid reactive species (TBA-RS), total radical-trapping antioxidant potential (TRAP), and total antioxidant
reactivity (TAR) in plasma of X-ALD patients, as well as the activities of the antioxidant enzymes catalase (CAT), superoxide dismutase
(SOD) and glutathione peroxidase (GPx) in erythrocytes and fibroblasts from these patients. It was verified a significant increase of plasma
chemiluminescence and TBA-RS, reflecting induction of lipid peroxidation, as well as a decrease of plasma TAR, indicating a deficient
capacity to rapidly handle an increase of reactive species. We also observed a significant increase of erythrocytes GPx activity and of catalase
and SOD activities in fibroblasts from the patients studied. It is therefore proposed that oxidative stress may be involved in pathophysiology
of X-ALD.
D 2003 Elsevier B.V. All rights reserved.Keywords: X-linked adrenoleukodystrophy; Oxidative stress; Free radical
1. Introduction (VLCFA), mainly hexacosanoic (C ) and tetracosanoicX-linked adrenoleukodystrophy (X-ALD) is the most
frequent peroxisomal disorder, with an estimated frequency
of 1:25,000 in males [1–3]. It should be differentiated
clinically and biochemically from neonatal ALD, an auto-
somal recessive disorder of peroxisome biogenesis in which
the function of at least five peroxisomal enzymes is im-
paired. Tissue accumulation of very long chain fatty acids0925-4439/$ - see front matter D 2003 Elsevier B.V. All rights reserved.
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acids (C24:0), is the biochemical hallmark of X-ALD, which
is caused by a defect in very long chain acyl-CoA synthetase
transport [1,5,6]. Fatty acids accumulation seems responsi-
ble for adrenal cortex malfunction and nervous system
demyelination [7,8]. Known clinical forms are classical (or
childhood) cerebral X-ALD (cALD), adrenomyeloneurop-
athy (AMN) and isolated Addison’s disease (AD). Patients
may be completely asymptomatic and several phenotypes
may occur in the same family [7,12]. cALD and AMN are
the two most frequent clinical forms of X-ALD [7,10].
AMN may be confounded with multiple sclerosis. Patients
with classical X-ALD usually develop the symptoms from
age 4 to 8, including visual and auditory disturbances,
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ing difficulties, demyelinization and leukodystrophy. The
disease progresses rapidly and untreated patients usually die
approximately 2 to 5 years after symptom onset [10,11]. In
contrast, AMN appears around age 20–30 [10,11] and is
characterized by progressive paraparesis and sphincter dis-
turbances because the spinal cord is affected. Two-thirds of
the X-ALD patients have adrenal insufficiency. Treatment
consists of a diet restricted in saturated fatty acids, com-
bined with the use of glycerotrioleate/glyceroltrierucate
(GTO/GTE), known as Lorenzo’s oil [2,9,13,14]. The
objective is to normalize VLCFA concentrations, but
favourable responses apparently occur only in patients
beginning treatment before the appearance of neurological
symptoms [1,2,9,13,15]. Bone marrow transplantation and
immunosuppression are also considered therapeutic alter-
natives [10]. Lovastatin and sodium phenylacetate were
tested as therapeutic drugs for normalizing VLCFA levels
in plasma and skin fibroblasts of X-ALD patients [16,17].
The peroxisome is a small cellular organelle involved in
both oxygen and lipid metabolism. Defects in peroxisomal
functions are associated with major, and often fatal, changes
at the neurological level during human development. The
neurological damage that occurs in X-ALD could be medi-
ated by astrocyte activation and cytokine pro-inflammatory
induction (tumoral necrose factor a, interleucine 1h and
interleucine 6) [3,4]. However, the exact mechanisms un-
derlying the brain damage in X-ALD are poorly known.
Lorenzo’s oil treatment is not directed to the neuroinflama-
tory aspects of X-ALD.
It has been shown in animal models that lovastatin (3-
hydroxy-3-methyl-glutaryl-CoA reductase inhibitor) and
sodium phenylacetate (pyrophosphate mevalonate decar-
boxilase inhibitor) inhibit nitric oxide synthetase induction
and the cytokine pro-inflammatory discharge involved in
pathogenesis of the neurological damage in X-ALD [16].
It was verified that these drugs normalize the VLCFA
levels in skin fibroblast of X-ALD patients with a con-
comitant decrease in VLCFA tissue levels [17]. Therefore,
it is possible that lovastatin could be promissory by
inhibiting the neuroinflammatory process characteristic of
X-ALD.
Free radicals seem to be involved in a large number of
human diseases. Increasing evidence shows that damage
caused by free radicals is an important contributing factor in
neurodegenerative, chronic-inflammatory, vasculary and
neoplasic diseases [18]. Brain has relatively low levels of
antioxidant defenses and a high lipid content with great
quantities of unsaturated fatty acids and cathecolamines,
which are highly susceptible to reactive oxygen species
attack. The involvement of free radicals in the pathophys-
iology of various common neurological diseases has been
described, including Parkinson’s disease, Alzheimer’s dis-
ease, strokes, multiple sclerosis and epilepsy [19–21].
Our objective in the present study was to determine
various parameters of oxidative stress in plasma, eryth-rocytes and cultured fibroblasts from X-ALD patients in
order to verify whether free radicals could be involved in
the pathophysiology of the tissue damage in these
patients.2. Materials and methods
2.1. Patients and controls
Plasma, erythrocytes and fibroblasts from 19 X-ALD
patients (13 cases of cALD and 6 cases of AMN) aged
between 5 and 38 years (meanF S.D.: 15.1F11 years old)
were used to evaluate the different parameters of oxidative
stress. The mean age for cALD and AMN were, respective-
ly, 8.38F 2.5 and 29.7F 9.5 years old. Clinical symptoms
of the cALD patients included leukodystrophy, learning
difficulty, seizures, hyperactivity and of AMN patients were
leukodystrophy, limb weakness, paraparesis, behavioral and
sphincter disturbances. Patients were diagnosed in our
laboratory by increased plasma levels of VLCFA detected
by gas chromatography [22]. The period between plasma
collection and analysis was always less than 2 weeks.
Plasma, erythrocytes and fibroblasts from controls were
obtained from healthy age-matched individuals (21.1F 8.1
years old).
2.2. Reagents
All chemicals were of PA purity and were purchased
from Sigma (St. Louis, MO) except TBA, which was from
Merck (Darmstadt, Germany). Chemiluminescence, total
antioxidant reactivity (TAR) and total radical-trapping anti-
oxidant potential (TRAP) were assayed using a beta liquid
scintillation spectrometer (Tricarb 2100 and Wallac model
1409, respectively) and TBA-RS was measured with a
double-bean spectrophotometer with temperature control
(Hitachi U-2001).
2.3. Preparation of erythrocytes, plasma and fibroblasts
Erythrocytes and plasma were prepared from whole
blood samples obtained from fasting individuals (controls
and X-ALD) by venous puncture with heparinized vials.
Whole blood was centrifuged at 3000 rpm, and the plasma
was immediately removed by aspiration and frozen at  80
jC until determination. Erythrocytes were washed three
times with cold saline solution (sodium chloride 0.153
mol/l). Lysates were prepared by addition of 100 Al of
washed erythrocytes in 1 ml of distilled water and frozen at
 80 jC until determination of the antioxidant enzyme
activities.
Skin biopsies were taken and placed in polyethylene
sterile vials (type Falcon T25) for culture cells. The primary
and secondary cultures were carried out in HAM-F10
culture medium supplemented with 20% of fetal bovine
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was achieved, the fibroblasts were collected and frozen in
liquid nitrogen until enzymatic activity determination,
which was performed in less than 2 weeks [23].
For antioxidant enzyme activity determination, erythro-
cytes were frozen/thawed three times and centrifuged at
9200 rpm for 10 min. The supernatants were diluted to
approximately 0.5 mg/ml of protein. Fibroblast extracts
were resuspended with 20 mM sodium phosphate buffer
containing 140 mM KCl and 0.1 M phenylmethasulfonyl
fluoride, pH 7.4; the pellet was measured and buffer was
added in a volume 10 times higher. The cells were frozen in
liquid nitrogen and thawed in water at 37 jC. This process
was repeated twice. The suspension was centrifuged at
3000 rpm for 10 min and the supernatant was used for
the tests.
2.4. Chemiluminescence
Samples were assayed for chemiluminescence in a dark
room by the method of Gonzalez-Flecha et al. [24]. Incu-
bation flasks contained 3.5 ml of medium consisting of 20
mM sodium phosphate, pH 7.4, and 140 mM KCl. The
background chemiluminescence was measured and 0.5 ml
of plasma, at a protein concentration of 0.5 mg/ml, was
immediately added to the incubation medium. Chemilumi-
nescence was measured for 10 min at room temperature.
The background chemiluminescence was subtracted from
the total value. Chemiluminescence was calculated as cpm/
mg protein.
2.5. Thiobarbituric acid reactive species (TBA-RS)
TBA-RS were determined according to the method
described by Esterbauer and Chesseman [25]. Briefly, 300
Al of 10% trichloroacetic acid was added to 150 Al of
plasma and centrifuged at 300 g for 10 min at 4 jC.
Three hundred microliters of the supernatant was transferred
to a vial and incubated with 300 Al 0.67% thiobarbituric
acid (in 7.1% sodium sulfate) at 100 jC for 25 min. The
mixture was allowed to cool on water for 5 min. The
resulting pink-stained TBA-RS were determined in a spec-
trophotometer (Hitachi U-2001) at 535 nm. The acid did not
produce color when tested without the addition of the
sample, demonstrating the absence of a direct reaction toTable 1
Chemiluminescence and TBARS parameters in plasma of X-ALD patients
Assays Control
MeanF S.D. Range
Chemiluminescence (n= 3) 104F 56.1 47.5–160
TBA-RS (n= 7) 0.15F 0.08 0.07–0.23
Plasma chemiluminescence from adrenoleukodystrophy patients and controls. C
meanF S.D. (n= 3). Difference from control, *P < 0.05 (non-paired Student’s t te
Plasma TBA-RS from adrenoleukodystrophy patients and controls. TBA-RS wer
(n= 7). Difference from control, **P < 0.01 (non-paired Student’s t test).TBA. Calibration curve was performed using 1,1,3,3-tetra-
methoxypropane and each curve point was subjected to the
same treatment as that of the supernatants. TBA-RS were
calculated as nmol TBA-RS/mg protein.
2.6. Total radical-trapping antioxidant potential (TRAP)
TRAP, representing the total antioxidant capacity of the
tissue, was determined by measuring the luminol chemilu-
minescence intensity induced by 2,2V-azo-bis-(2-amidino-
propane) (ABAP) according to the method of Lissi et al.
[26]. The background chemiluminescence was measured by
adding 4 ml of 10 mM ABAP (in 0.1 M glycine buffer, pH
8.6) into a glass scintillation vial. Ten microliters of luminol
was added to each vial and the chemiluminescence was
measured. This was considered to be the initial value. Ten
microliters of 300 AM Trolox or plasma was added and the
chemiluminescence was measured until it reached the initial
levels. The addition of Trolox or supernatant to the incuba-
tion medium reduces the chemiluminescence. The time
necessary for the chemiluminescence intensity to return to
the initial value was considered to be the induction time
(IT). IT is directly proportional to the antioxidant capacity of
the tissue and the IT of each sample was compared with the
IT of Trolox. TRAP values are expressed as nM Trolox/mg
protein.
2.7. Total antioxidant reactivity (TAR)
TAR, which represents the quality of the tissue antiox-
idants, was determined by measuring the luminol chemi-
luminescence intensity induced by ABAP according to the
method of Lissi et al. [27]. The background chemilumi-
nescence was measured by adding 4 ml of 2 mM ABAP
(in 0.1 M glycine buffer, pH 8.6) into a glass scintillation
vial. Fifteen microliters of luminol (4 mM) was added to
each vial and the chemiluminescence was measured. This
was considered to be the basal value. Ten microliters of 10
AM Trolox or plasma (prepared in the same buffer as for
TRAP) was then added and the chemiluminescence was
measured during 60 s. The Trolox or supernatant addition
reduces the chemiluminescence. The rapid reduction in
luminol intensity is considered as a measure of the TAR
capacity. TAR measurement was calculated as nmol Tro-
lox/mg protein.X-ALD patient Phenotype
MeanF S.D. Range
272F 69.9* 202–342 Cerebral ALD
0.32F 0.08** 0.24–0.40 5 Cerebral ALD 2 AMN
hemiluminescence was calculated as cpm/mg protein. Data represent the
st).
e calculated as nmol TBA-RS/mg protein. Data represent the meanF S.D.
Table 2
TAR and TRAP parameters in plasma of X-ALD patients
Assays Control X-ALD patient Phenotype
MeanF S.D. Range MeanF S.D. Range
TRAP (n= 4) 1053F 379.48 674–1433 992F 384 608–1376 Cerebral ALD
TAR (n= 8) 90.3F 38.3 51.9–129 49.7F 24.8** 24.8–74.5 4 Cerebral ALD 4 AMN
Plasma TRAP from adrenoleukodystrophy patients and controls. TRAP values are expressed as nM Trolox/mg protein. Data represent the meanF S.D. (n= 4).
No significance was detected (non-paired Student’s t test).
Plasma TAR from adrenoleukodystrophy patients and controls. TAR measurement was calculated as nmol Trolox/mg protein. Data represent the meanF S.D.
(n= 8). Difference from control, **P < 0.01 (non-paired Student’s t test).
Table 3
Antioxidant enzyme activities in erythrocytes of X-ALD patients
Antioxidant Control X-ALD patient Phenotype
Enzyme
MeanF S.D. Range MeanF S.D. Range
Cat
(n= 4)
3.13F 0.33 2.80–3.46 2.57F 0.57 2.00–3.14 Cerebral
ALD
GPx
(n= 4)
0.83F 0.12 0.71–0.95 0.94F 0.12* 0.82–1.06 Cerebral
ALD
SOD
(n= 4)
1.03F 0.42 0.61–1.45 1.11F 0.41 0.70–1.52 Cerebral
ALD
CAT: catalase (pmol/mg prot); GPx: glutathione peroxidase (mU/mg prot);
SOD: superoxide dismutase (U/mg prot). One unit is defined as 1 Amol of
NADPH consumed per minute for GPx and 50% of produced chromogen
inhibition for SOD. Data represent the meanF S.D. (n= 4). Difference from
control, *P < 0.05 (non-paired Student’s t test).
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2.8.1. Catalase assay (CAT)
CAT activity was assayed by the method of Aebi [28] by
measuring the absorbance decrease at 240 nm in a reaction
medium containing 20 mM H2O2, 10 mM potassium
phosphate buffer, pH 7.0, and 0.1–0.3 mg protein/ml.
One unit of the enzyme is defined as 1 Amol of H2O2
consumed per minute and the specific activity is reported as
units per milligram of protein.
2.8.2. Glutathione peroxidase (GPx)
GPx was measured by the method of Wendel [29] using
tert-butyl-hydroperoxide as substrate. The activity was
determined monitoring the NADPH disappearance at 340
nm in a medium containing 2 mM glutathione, 0.15 U/ml
glutathione reductase, 0.4 mM azide, 0.5 mM tert-butyl-
hydroperoxide and 0.1 mM NADPH. One GPx unit is
defined as 1 Amol of NADPH consumed per minute and
the specific activity is represented as units per milligram of
protein.
2.8.3. Superoxide dismutase (SOD)
SOD activity was determined using the RANSOD kit
(Ransox, Antrim, United Kingdom). The method is based
on the formation of red formazan from the reaction of 2-(4-
iodophenyl)-3-(4-nitrophenol)-5-phenyltetrazolium chloride
and superoxide radical (produced in the incubation medium
from the xanthine–xanthine oxidase reaction system),
which is assayed spectrophotometrically at 505 nm. The
inhibition of the produced chromogen is proportional to the
activity of the SOD present in the sample. A 50% inhibition
is defined as 1 U of SOD and the specific activity is
represented as units per milligram of protein.
2.9. Protein determination
Protein concentrations were determined by the method of
Lowry et al. [30], using bovine serum albumin as standard.
2.10. Statistical analysis
Data are expressed as meanF standard deviation. The
Student’s t test for non-paired samples was used to compare
results from controls and X-ALD patients. A P value of lessthan 0.05 was considered to be significant. All analyses
were performed using the Statistical Package for the Social
Sciences (SPSS) software in a PC-compatible computer.3. Results
The lipid peroxidation parameters chemiluminescence
and TBA-RS were determined in plasma of X-ALD
patients. Table 1 shows that chemiluminescence was signif-
icantly increased by 264% (from 104 to 272) [t(4) = 8.053,
P < 0.05] in plasma of cALD patients, as compared to
controls. Furthermore, TBA-RS measurement was also
significantly increased by 215% (from 0.15 to 0.32)
[t(12) = 3.913, P < 0.01] in plasma from these patients (5
cALD and 2 AMN) (Table 1). These results strongly
indicate that lipid peroxidation is stimulated in X-ALD.
We also observed that TRAP measurement, which is
indicative of the tissue nonenzymatic antioxidant defenses,
was not altered in plasma of cALD patients [t(6) = 0.181,
P > 0.05] (Table 2). However, TAR measurement, which is a
measure of the tissue capacity to react with free radicals,
was markedly reduced (43%) [t(14) = 2.515; P < 0.01] (90.3
to 49.7) (Table 2). These results suggest that the overall
content of nonenzymatic antioxidants was not significantly
altered in plasma of X-ALD patients, in contrast with the
antioxidant reactivity (TAR), which was significantly de-
creased, indicating a deficient capacity of the tissue to
modulate the damage associated with the enhanced produc-
tion of reactive species.
Table 4
Antioxidant enzyme activities in fibroblasts of X-ALD patients
Antioxidant Control X-ALD patient Phenotype
enzyme
Values Range Values Range
Cat
(n= 2)
0.053 0.113 0.05–0.11 1.45
1.73
1.45–1.73 Cerebral
ALD
SOD
(n= 2)
0.40 0.58 0.40–0.58 1.70
1.85
1.70–1.85 Cerebral
ALD
CAT: catalase (pmol/mg prot); SOD: superoxide dismutase (U/mg prot).
Data represent the meanF S.D. One unit is defined as 50% of produced
chromogen inhibition for SOD.
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enzymes CAT, GPx and SOD in erythrocytes and fibro-
blasts. It can be seen in Tables 3 and 4 that these activities
were altered in both tissues from X-ALD patients. A
moderate but significant increase (13%) of GPx activity
[t(6) = 4.599, P < 0.05] was detected in erythrocytes (Table
3). It can be also seen that catalase and SOD activities were
much greater (1887% and 262% increase, respectively) in
fibroblasts from two cALD patients, as compared to controls
(Table 4).4. Discussion
Neurological symptoms and brain abnormalities are
characteristic of patients affected by X-ALD. However, very
little is known about the pathomechanisms involved in the
tissue damage of this disorder. In the present study we
investigated various parameters of oxidative stress in plas-
ma, erythrocytes and cultured fibroblasts from X-ALD
patients. We verified a significant increase of chemilumi-
nescence and TBA-RS in the plasma from these patients.
Considering that light emitted in the chemiluminescence
assay usually arises from peroxidizing lipids due to an
increase in reactive oxygen or nitrogen species production
and that TBA-RS reflects the amount of malondialdehyde
formation, an end product of membrane fatty acid perox-
idation [31], our data indicate that lipid peroxidation is
induced in plasma of X-ALD, which probably occurs due to
increased free radical generation.
It was also demonstrated that TRAP measurement was
not altered in the patients plasma, indicating no alteration in
the content of nonenzymatic antioxidant defenses. Since the
major contributors of TRAP value in plasma are urate,
plasmatic proteins, ascorbic acid and vitamin E, it is feasible
that the concentrations of these substances are not modified
in plasma from X-ALD patients. This should be, however,
tested in future studies. In contrast, a significant decrease of
TAR measurement was found in plasma of the affected
patients, reflecting a deficient capacity to rapidly handle an
increase of reactive species. It should be noted that TAR
corresponds to a useful index of the capacity of a given
tissue to modulate the damage associated with an increased
production of free radicals and reflects not only the quantityof antioxidants (given by TRAP), but also, and particularly,
its quality (given by its reactivity) [26]. Given the above
results of increased lipid peroxidation, which indirectly
reflects greater reactive species formation, it may be pre-
sumed that TAR measurement is a more sensitive marker of
free radical production than TRAP in vivo. We have
previously observed that TRAP measurement was not
altered by in vitro 3-hydroxy glutaric acid in rat cerebral
cortex whereas TAR was significantly decreased by the
same doses of the metabolite [32], a fact that agrees with
this hypothesis.
In this study we also demonstrated an increase of
erythrocyte GPx activity and of catalase and SOD activities
in fibroblasts from patients, as compared to the controls.
The significant increase of these antioxidant enzyme activ-
ities may have been a response to high sustained levels of
reactive species in X-ALD patients. The increase of catalase
and GPX activity suggests that oxygen peroxide is formed
in excess, whereas the increase of SOD suggests that
superoxide is formed in excess. Peroxisomes contain many
of the cellular enzymes that generate H2O2, such as glyco-
late oxidase, urate oxidase and flavoprotein dehydrogenases
involved in the h oxidation of fatty acids, a metabolic
pathway that operates in mitochondria and peroxisomes of
animal tissues [33]. In peroxisomes the flavoproteins react
with O2 to give rise to H2O2. It seems logical therefore that
these enzymes are packaged into an organelle with high
capacity to destroy H2O2.
On the other hand, taken together our present data
showing a significant increase of chemiluminescence and
TBA-RS levels and a diminution of TAR in plasma, and
considering that an unbalance between the total antioxidant
defenses and the reactive species formed in the tissues is
indicative of oxidative stress [34], it is proposed that free
radical generation is involved in the pathophysiology of the
tissue damage found in X-ALD. Our results on the alter-
ations of the antioxidant enzymatic activities in erythrocytes
and fibroblasts strongly corroborate with this presumption.
It should be pointed out that most assays were performed
using specimens exclusively from cALD patients, so that
conclusions from the results of these assays should be
directed to this phenotype. However, as far as TAR and
TBA-RS measurements are concerned, we used samples
from cALD and AMN patients. In this case, although the
individual values do not appear in the tables, there was no
visual difference between these values obtained from the
two distinct phenotypes, suggesting that oxidative stress
also occurs in the AMN phenotype. However, further
experiments should be conducted to clarify this matter.
At this point, it should be emphasized that the brain has
low antioxidant defenses compared with other tissues [35], a
fact that makes this tissue more vulnerable to increased
reactive species. Mounting evidence has shown that oxida-
tive stress has been implicated in the pathophysiology of
common neurodegenerative disorders, such as Parkinson’s
disease, Alzheimer’s disease, multiple sclerosis as well as in
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fore, considering that free radicals are also produced in
the brain similarly to what occurs in plasma, as here
demonstrated, and that the antioxidant defenses are reduced
in this tissue as occurred in fibroblasts and erythrocytes, it
may be presumed that oxidative stress may compromise the
brain, in X-ALD similarly to what occurs in the above
mentioned neurodegenerative disorders.
Our results should be taken with caution and confirmed
with a higher number of patients and with other techniques
to measure oxidative stress since we used specimens from
only a few patients. In this context, CSF specimens maybe
useful to evaluate whether brain is also a target for reactive
species. If they are confirmed, we may conclude that
oxidative stress contributes at least in part to the pronounced
neurological dysfunction found in X-ALD. In this scenario,
it has been proposed that the neurological damage that
occurs in X-ALD could be mediated by astrocyte activation
and cytokine pro-inflammatory induction. Since free radi-
cals are also involved in inflammatory response, our find-
ings and these observations may reflect the same
phenomenon. Finally, since so far no therapy for X-ALD
has been proven to be successful, it may also be presumed
that the administration of antioxidants should be considered
as a potential therapy for the patients affected by X-ALD.Acknowledgements
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